Chelsey White, DO
Pulmonary Disease · Ashland, KYNPI 1073938874
Payments from drug & device makers
Across 399 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$554
- Grifols USA, LLC$544
- Takeda Pharmaceuticals U.S.A., Inc.$419
- Novartis$389
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,173100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 130 | $2,310 |
| AstraZeneca | 42 | $1,248 |
| Sanofi | 23 | $554 |
| Grifols USA, LLC | 21 | $544 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $419 |
| Novartis | 19 | $389 |
| Genentech USA, Inc. | 20 | $332 |
| Verona Pharma, Inc. | 16 | $316 |
| Boehringer Ingelheim | 14 | $291 |
| Regeneron Healthcare Solutions, Inc. | 12 | $268 |
| Mylan Specialty L.p. | 8 | $206 |
| United Therapeutics Corporation | 12 | $205 |
| Johnson & Johnson | 10 | $164 |
| Electromed, Inc. | 13 | $162 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $119 |
| Amgen | 6 | $116 |
| Philips North America LLC | 5 | $97 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Pulmonx Corporation | 1 | $37 |
| Medical Graphics Corporation | 1 | $34 |
| Vifor Pharma, Inc. | 1 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Bayer | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Circassia Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Merck | 1 | $25 |
| Viatris Specialty LLC | 1 | $21 |
| Insmed, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$624
- FASENRA$624
- AIRSUPRA$481
- BREZTRI$424
- BEVESPI AEROSPHERE$143
- Prolastin-C Liquid$125
How this compares
$8,185 in reported general payments places this provider in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,202 | $974,724 |
| NucalaMepolizumab | 57 | $214,034 |
| OfevNintedanib Esylate | 14 | $211,218 |
| Dupixent PenDupilumab | 28 | $134,730 |
| Dupixent SyringeDupilumab | 35 | $131,220 |
| Fasenra PenBenralizumab | 23 | $128,498 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $99,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $72,339 |
| Spiriva RespimatTiotropium Bromide | 71 | $70,763 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $33,941 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $26,374 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $26,013 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 781 | $23,948 |
| EliquisApixaban | 39 | $22,300 |
| Ventolin HfaAlbuterol Sulfate | 250 | $19,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,310 | $1,324,5581,507 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $291 | $315,922148 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,248 | $89,119153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sana GhalibAshland$16K
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- Mena ShehataAshland$11K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.